Source: Fox News
Summary
A comprehensive review of 54 randomized controlled trials found little strong evidence that medicinal cannabinoids help with mental disorders and substance-use disorders. Researchers at the University of Sydney, Australia, analyzed data from 2,477 participants and found that cannabinoids were “rarely justified” for routine use, with a 75% higher risk of adverse side effects. The study did find promise for treating cannabis use disorder, insomnia, Tourette’s symptoms, and autistic traits, but the evidence was still low quality. The researchers questioned the approval of medicinal cannabis for the treatment of depression, anxiety, and PTSD.
Our Reading
The advice sounds familiar.
The use of medicinal cannabinoids for mental health conditions has been a topic of debate, with some studies suggesting benefits and others finding no evidence of effectiveness. This new review is the most comprehensive attempt to date to evaluate cannabis specifically for anxiety, depression, and PTSD. However, the researchers noted that the risk of adverse side effects was higher, and the evidence for benefits was low quality. It seems that the use of medicinal cannabinoids for mental health conditions is still a topic of ongoing research and debate.
The study’s findings are a reminder that the effectiveness of medicinal cannabinoids for mental health conditions is not yet fully understood, and more research is needed to determine their potential benefits and risks.
As one expert noted, “Using cannabis to manage emotional distress may delay access to proven treatments.” This highlights the importance of careful consideration and consultation with healthcare professionals before using medicinal cannabinoids for mental health conditions.
The study’s results also underscore the need for high-quality research and evidence-based decision-making in the field of medicinal cannabinoids.
It’s a familiar pattern: a new study challenges previous findings, and the debate continues.
Author: Evan Null
